Technical Analysis for CRNX - Crinetics Pharmaceuticals, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| B | 44.41 | -2.12% | -0.96 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Resistance | Bearish | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 50 DMA Resistance | Bearish | -2.12% | |
| Calm After Storm | Range Contraction | -2.12% | |
| Outside Day | Range Expansion | -2.12% |
| Alert | Time |
|---|---|
| Down 2 % | 2 days ago |
| Lower Bollinger Band Support | 2 days ago |
| Fell Below Lower Bollinger Band | 2 days ago |
| Down 1% | 2 days ago |
| Outside Day | 2 days ago |
Get a Trading Assistant
- Earnings date: 05/09/2024
Crinetics Pharmaceuticals, Inc. Description
Crinetics Pharmaceuticals, Inc. is a clinical stage pharmaceutical company. The Company is focused on the discovery and development of drugs to treat specialty endocrine diseases and endocrine-related tumors. It develops a pipeline of oral nonpeptide chemical entities that target peptide G protein coupled receptors (GPCRs) for the treatment of endocrine diseases. The Company’s lead product candidate is CRN00808 developed for the treatment of acromegaly. It also develops two other product candidates CRN02481 for hyperinsulinemia, and CRN01941 for the treatment of neuroendocrine tumors. CRN02481 and CRN01941 are both oral nonpeptide somastatin receptors that are in the pre-clinical stages of development. The company also conducts research programs on developing nonpeptide products for the treatment of Cushing’s disease.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Disease Organ Systems Pancreatic Cancer Insulin Endocrine System Stage Pharmaceutical Chemical Entities Neuroendocrine Tumors Acromegaly Neuroendocrine Tumor Endocrine Disease Endocrine Diseases Neuroendocrinology
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 53.7 |
| 52 Week Low | 15.76 |
| Average Volume | 857,070 |
| 200-Day Moving Average | 35.43 |
| 50-Day Moving Average | 46.31 |
| 20-Day Moving Average | 48.50 |
| 10-Day Moving Average | 48.06 |
| Average True Range | 2.19 |
| RSI (14) | 39.76 |
| ADX | 21.45 |
| +DI | 21.01 |
| -DI | 23.25 |
| Chandelier Exit (Long, 3 ATRs) | 47.13 |
| Chandelier Exit (Short, 3 ATRs) | 50.24 |
| Upper Bollinger Bands | 52.63 |
| Lower Bollinger Band | 44.36 |
| Percent B (%b) | 0.01 |
| BandWidth | 17.05 |
| MACD Line | 0.07 |
| MACD Signal Line | 0.84 |
| MACD Histogram | -0.7751 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 48.58 | ||||
| Resistance 3 (R3) | 48.93 | 47.90 | 47.89 | ||
| Resistance 2 (R2) | 47.90 | 46.83 | 47.72 | 47.65 | |
| Resistance 1 (R1) | 46.15 | 46.18 | 45.64 | 45.80 | 47.42 |
| Pivot Point | 45.12 | 45.12 | 44.86 | 44.94 | 45.12 |
| Support 1 (S1) | 43.37 | 44.05 | 42.86 | 43.02 | 41.40 |
| Support 2 (S2) | 42.34 | 43.40 | 42.16 | 41.17 | |
| Support 3 (S3) | 40.59 | 42.34 | 40.94 | ||
| Support 4 (S4) | 40.24 |
